Patent US5011829A successfully refreshed from Google Patents.
US5011829A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition and method of inhibiting virus
Assignee: GD Searle LLC
•
Filing: 1989-06-02
•
Granted: 1991-04-30
•
Expires: 2009-06-02
Abstract
Abstract A pharmaceutical composition and a method of inhibiting human immunodeficiency virus (HIV) is disclosed which comprises administering to an HIV infected patient a synergistic combination of 3'-azido-3'-deoxythymidine (AZT) and N-butyl deoxynojirimycin (N-butyl DNJ) in an amount which achieves antiviral efficacy.
Inventors
- 👤 Martin S. Hirsch
- 👤 Victoria A. Johnson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 18:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
47 words
A method of treating an HIV infected patient which comprises administering to said patient a combination of 3'-azido-3'-deoxythymidine and N-butyl deoxynojirimycin, or their pharmaceutically acceptable salts, in an amount which achieves antiviral efficacy and which yields a dose level which produces a combination index less than 1.
Claim 2
Independent Claim
47 words
A method of treating an HIV infected patient which comprises administering to said patient a combination of 3'-azido-3'-deoxythymidine and N-butyl deoxynojirimycin, or their pharmaceutically acceptable salts, in an amount which achieves antiviral efficacy and which yields a dose level which produces a combination index less than 1.
Claim 3
Dependent Claim
25 words
The method according to claim 1 wherein the 3'-azido-3'-deoxythymidine is administered to said patient in an amount from about 50 mg/day to about 1.2 g/day.
Claim 4
Dependent Claim
25 words
The method according to claim 1 wherein the 3'-azido-3'-deoxythymidine is administered to said patient in an amount from about 200 mg/day to about 1000 mg/day.
Claim 5
Dependent Claim
25 words
The method according to claim 1 wherein the 3'-azido-3'-deoxythymidine is administered to said patient in an amount from about 300 mg/day to about 800 mg/day.
Claim 6
Dependent Claim
26 words
The method according to claim 1 wherein the N-butyl deoxynojirimycin is administered to said patient in an amount from about 1 mg/kg/day to about 500 mg/kg/day.
Claim 7
Dependent Claim
26 words
The method according to claim 1 wherein the N-butyl deoxynojirimycin is administered to said patient in an amount from about 8 mg/kg/day to about 165 mg/kg/day.
Claim 8
Dependent Claim
26 words
The method according to claim 1 wherein the N-butyl deoxynojirimycin is administered to said patient in an amount from about 20 mg/kg/day to about 130 mg/kg/day.
Claim 9
Dependent Claim
26 words
The method according to claim 1 wherein the N-butyl deoxynojirimycin is administered to said patient in an amount from about 25 mg/kg/day to about 100 mg/kg/day.
Claim 10
Dependent Claim
15 words
The method according to claim 1 wherein the combination is administered to said patient orally.
Claim 11
Dependent Claim
15 words
The method according to claim 1 wherein the combination is administered to said patient intravenously.
Claim 12
Dependent Claim
25 words
The method according to claim 1 wherein the molar ratio of 3'-azido-3'-deoxythymid N-butyl deoxynojirimycin administered to said patient ranges from about 1:50 to about 1:100.
Claim 13
Dependent Claim
25 words
The method according to claim 1 wherein the molar ratio of 3'-azido-3'-deoxythymidine to N-butyl deoxynojirimycin administered to said patient ranges from about 1:60 to 1:80.
Claim 14
Dependent Claim
22 words
The method according to claim 1 wherein the molar ratio of 3'-azido-3'-deoxythymidine to N-butyl deoxynojirimycin administered to said patient is about 1:70.
Claim 15
Dependent Claim
22 words
The method according to claim 1 wherein the 3'-azido-3'-deoxythymidine and the N-butyl deoxynojirimycin are administered to said patient in separate, distinct dosages.
Claim 16
Dependent Claim
24 words
The method according to claim 1 wherein the 3'-azido-3'-deoxythymidine and the N-butyl deoxynojirimycin administered to said patient are combined in a single dosage form.
Claim 17
Dependent Claim
37 words
A pharmaceutical composition containing a combination of 3'-azido-3-deoxythymidine and N-butyl deoxynojirimycin, or their pharmaceutically acceptable salts, in an amount which achieves antiviral efficacy and which yields a dose level which produces a combination index less than 1.
Claim 18
Dependent Claim
37 words
A pharmaceutical composition containing a combination of 3'-azido-3-deoxythymidine and N-butyl deoxynojirimycin, or their pharmaceutically acceptable salts, in an amount which achieves antiviral efficacy and which yields a dose level which produces a combination index less than 1.
Claim 19
Dependent Claim
26 words
The pharmaceutical composition according to claim 16 wherein the molar ratio of 3'-azido-3'-deoxythymidine to N-butyl deoxynojirimycin in said composition is from about 1:50 to about 1:100.
Claim 20
Dependent Claim
18 words
The pharmaceutical composition according to claim 17 wherein the molar ratio is from about 1:60 to about 1:80.
Claim 21
Dependent Claim
14 words
The pharmaceutical composition according to claim 17 wherein the molar ratio is about 1:70.
Claim 22
Dependent Claim
10 words
The pharmaceutical composition of claim 16 formulated for oral administration.
Claim 23
Dependent Claim
10 words
The pharmaceutical composition of claim 16 formulated for intravenous administration.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-04-29 | 1994-10-29 | 1995-04-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-04-29 | 1998-10-29 | 1999-04-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-04-29 | 2002-10-29 | 2003-04-30 | $7700.00 | Window Closed / Lapsed |